GenentaScience's profile picture. Genenta is a clinical stage immuno oncology-company

Genenta Science (NASDAQ:GNTA)

@GenentaScience

Genenta is a clinical stage immuno oncology-company

Genenta Science (NASDAQ:GNTA) reposted

@GenentaScience $GNTA New Coverage Update by @ROTHCapital - BUY - TP $15

pigiparacchi's tweet image. @GenentaScience $GNTA New Coverage Update by @ROTHCapital - BUY - TP $15

Genenta Science (NASDAQ:GNTA) reposted

"Strategico avere sperimentazioni cliniche e pre-cliniche in Italia per impatto rilevante sulla vita di tutti noi. Alla base dello sviluppo di una nuova #terapia ci sono le #imprese, grandi ma anche medio-piccole". Il nostro consigliere @pigiparacchi live: bit.ly/42VmfKS

AssobiotecNews's tweet image. "Strategico avere sperimentazioni cliniche e pre-cliniche in Italia per impatto rilevante sulla vita di tutti noi. Alla base dello sviluppo di una nuova #terapia ci sono le #imprese, grandi ma anche medio-piccole". Il nostro consigliere @pigiparacchi live: bit.ly/42VmfKS

Genenta Science (NASDAQ:GNTA) reposted

Awesome


Genenta Science (NASDAQ:GNTA) reposted

Nucleate welcomes this conversation on connecting international biotech investors and founders in Italy. We thank our Nucleate Italy and @pigiparacchi for organizing.

thanks for taking part of Innovit for Life Sciences! @Assobiotec @pigiparacchi @NucleateHQ



Genenta Science (NASDAQ:GNTA) reposted

Da un'idea alla quotazione in borsa: quella di @GenentaScience è la storia di un vero caso di successo. Al #SIOS23 Summer ci sarà @pigiparacchi, CEO e co-founder di Genenta Science (Nasdaq: $GNTA) Registrati👉 bit.ly/43c3FPk Main partner @SACEgroup in collab. @UniLUISS

startup_italia's tweet image. Da un'idea alla quotazione in borsa: quella di @GenentaScience è la storia di un vero caso di successo. Al #SIOS23 Summer ci sarà @pigiparacchi, CEO e co-founder di Genenta Science (Nasdaq: $GNTA)
Registrati👉 bit.ly/43c3FPk
Main partner @SACEgroup  in collab. @UniLUISS

thanks for taking part of Innovit for Life Sciences! @Assobiotec @pigiparacchi @NucleateHQ

Join the the first fireside chat #InnovitforLifeSciences that brings together the competitiveness of 🇮🇹 Life Sciences 🩺and the experience of 🇺🇸 Investors 🎆 Registration: bit.ly/27June23 @GenentaScience @NIH

issnaf's tweet image. Join the the first fireside chat #InnovitforLifeSciences that brings together the competitiveness of 🇮🇹 Life Sciences 🩺and the experience of 🇺🇸 Investors 🎆
Registration: bit.ly/27June23
@GenentaScience @NIH


Join us for a live session that brings together the competitiveness of Italian Life Sciences and the experience of US Investors. Innovit for Life Sciences > Road to #JPM24 On Tuesday 27th June 2023 10.30am EDT - 4.30pm CET @GenentaScience @AssobiotecF

GenentaScience's tweet image. Join us for a live session that brings together the competitiveness of Italian Life Sciences and the experience of US Investors.

Innovit for Life Sciences > Road to #JPM24

On Tuesday 27th June 2023 10.30am EDT - 4.30pm CET
@GenentaScience @AssobiotecF

@GenentaScience is at Sidoti Virtual Event May 10 2023 with our @pigiparacchi CEO and Co-founder , join us

See these #healthcare management teams present live and submit your questions during their Q&A. $ACU $CYTO $ANPC $BXRX $CRDL $COYA $HUGE $GNTA $GNPX $HILS $HUMA $INFU $IKT $KTRA ow.ly/fqFJ30svfWR All investors are welcome to join free of charge: ow.ly/KCPS30svfWS

SidotiResearch's tweet image. See these #healthcare management teams present live and submit your questions during their Q&A. $ACU $CYTO $ANPC $BXRX $CRDL $COYA $HUGE $GNTA $GNPX $HILS $HUMA $INFU $IKT $KTRA

ow.ly/fqFJ30svfWR

All investors are welcome to join free of charge:
ow.ly/KCPS30svfWS


True or False: Cell therapy refers to the transfer of autologous or allogeneic cellular material into a patient for medical purposes

True %100
False %0

4 vote · Final results


Our lead candidate is a lenti-virus based hematopoietic stem progenitor cell #immunotherapy enabling controlled and targeted interferon-α expression within #cancers. Learn more: bit.ly/3VGjoT3

GenentaScience's tweet image. Our lead candidate is a lenti-virus based hematopoietic stem progenitor cell #immunotherapy enabling controlled and targeted interferon-α expression within #cancers. Learn more: bit.ly/3VGjoT3

At Genenta, our scientists bring a unique blend of multi-disciplinary competence, vast experience in #CellTherapy, and a commensurate track-record in the forefront of therapies and #DrugDevelopment. Learn more: bit.ly/40xHqBL

GenentaScience's tweet image. At Genenta, our scientists bring a unique blend of multi-disciplinary competence, vast experience in #CellTherapy, and a commensurate track-record in the forefront of therapies and #DrugDevelopment. Learn more: bit.ly/40xHqBL

Meet Richard B. Slansky, Chief Financial Officer at Genenta! Richard is a senior financial executive with more than 30 years of experience at various #biopharmaceutical diagnostic and life science companies. Learn more: bit.ly/3ZV3yGf

GenentaScience's tweet image. Meet Richard B. Slansky, Chief Financial Officer at Genenta! Richard is a senior financial executive with more than 30 years of experience at various #biopharmaceutical diagnostic and life science companies. Learn more: bit.ly/3ZV3yGf

We're #hiring a new Genenta Science VP Business Development based in New York, New York, United States. Apply today or share this post with your network linkedin.com/feed/update/ur…


Our platform technology triggers the production of alpha-interferon as a therapeutic inside the tumors through a transgene expression control vector, allowing for a robust anti-cancer response with potential minimized systemic toxicity. Check out our MOA: bit.ly/3FXShxs


Loading...

Something went wrong.


Something went wrong.